Cargando…

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

INTRODUCTION: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a real-world se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gkalpakiotis, Spyridon, Cetkovska, Petra, Arenberger, Petr, Dolezal, Tomas, Arenbergerova, Monika, Velackova, Barbora, Fialova, Jorga, Kojanova, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179080/ https://www.ncbi.nlm.nih.gov/pubmed/34089479 http://dx.doi.org/10.1007/s13555-021-00556-2

Ejemplares similares

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic
por: Kojanova, Martina, et al.
Publicado: (2021)

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
por: Hugo, Jan, et al.
Publicado: (2023)

Isolated Melanocytic Hyperpigmentation of the Distal Digits – A Case Report and Review of the Literature
por: Marques, Emanuel C., et al.
Publicado: (2022)

Unusual Periungual Nodulocystic Lesions Leading to the Diagnosis of Extranodal Marginal Zone Lymphoma
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Clinical results of the application of a hemoglobin spray to promote healing of chronic wounds
por: Arenberger, Peter, et al.
Publicado: (2011)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Analysis of Obligatory Involvement of Medical Students in Pandemic Response in the Czech Republic: Competencies, Experiences, and Legal Implications
por: Michenka, Petr, et al.
Publicado: (2022)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
por: Gracia-Cazaña, Tamara, et al.
Publicado: (2023)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Associations between migraine and possible risk factors in the Czech Republic
por: Riedlova, Petra, et al.
Publicado: (2023)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
por: Al Muqrin, Abdullah Muqrin, et al.
Publicado: (2022)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study
por: Arenberger, Petr, et al.
Publicado: (2017)

Pharmacy Practice and Education in the Czech Republic †
por: Nachtigal, Petr, et al.
Publicado: (2017)

Social costs of obesity in the Czech Republic
por: Landovská, Petra, et al.
Publicado: (2022)

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
por: Cetkovská, Petra, et al.
Publicado: (2023)

Sharing datasets of the COVID-19 epidemic in the Czech Republic
por: Komenda, Martin, et al.
Publicado: (2022)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Czech multicenter research database of severe COPD
por: Novotna, Barbora, et al.
Publicado: (2014)

Mosquitoborne Viruses, Czech Republic, 2002
por: Hubálek, Zdenek, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_hl7v885qovjb19ah1peu9njeae